• Located in 🇨🇦 Hamilton, Ontario
  • 2,300 participants expected 🌎 worldwide
  • HMRG established in 1997
Start live chat

Have you tested COVID-19 positive, in the last five days?

Participate in a Research Study in Hamilton!

Dr. Richard Tytus is looking at a potential new oral drug for adults with COVID-19 who are at risk for serious disease. Your participation in this study can help advance COVID-19 research to find more safe and effective treatments.
  • Obtain study-related medical care during the study
  • Help to advance COVID-19 research 😷
  • Located in Hamilton 🇨🇦
Check your eligibility now
Learn more

Approved by Research Ethics Board. No obligation.

Meet Richard Tytus, Family Doctor & Founder of Hamilton Medical Research Group

My vision: A community in which everyone is able to achieve their optimal level of health and wellness by enabling the introduction and innovation of new treatments and therapies.
Dr. Richard Tytus practised as a GP anesthetist for five years in Blind River, Ontario, before practising in downtown Hamilton. He is an associate clinical professor in the Department of Family Medicine at McMaster University. Dr. Tytus served as president of the Hamilton Academy of Medicine and is currently a director of the Ontario Medical Association (OMA) Board (District 4).
 
Dr. Tytus has received numerous awards, including the 2012 Family Physician of the Year presented by the Ontario College of Family Physicians.
Are you eligible to participate?

Take a more active role in your health care today.

Check your eligibility
Learn more
Dr. Richard Tytus is looking at a potential new oral drug for adults with COVID-19 who are at risk for serious disease.
Hamilton Medical Research Group
700 Main Street East
Hamilton, Ontario  L8M 1K7
 

© Copyright 2023, All Rights Reserved by Banty (our partner in clinical trial recruitment)

Study Summary

The BIRCH Study is testing the effectiveness and safety of a potential new oral drug for COVID-19 called GS-5245. Researchers want to see if it can lower the chance for serious disease and the need to be hospitalized.

Being in the study is voluntary. Even if you decide to join and then change your mind, you can stop participating at any time.

To be considered for the study, you must:

  • Be 18 years of age or older.
  • Have tested positive for COVID-19 in the last 5 days.
  • Have had COVID-19 symptoms for no more than 5 days.
  • Be at risk for developing serious disease.
  • Not be currently hospitalized or require hospitalization.

You may be at risk for serious disease if you are 50 years of age or older and/or have certain medical conditions, such as cancer, heart disease, kidney disease, lung disease, diabetes, or HIV. These are not all of the risk factors. Talk to your doctor to learn more.

The study doctor will first explain all the details of the study and hand you a document called the Informed Consent Form. Think it over and ask any questions you have. If you agree to join, you will give your permission by signing the form before any study tests can begin.

To see if you qualify, the study team will collect information about your health and medical history and run some tests. This is called screening. If you qualify, your first study visit and study drug dose may occur on the same day.

The study lasts about 29 days, with at least 6 visits for tests and health checks. At least 2 visits will be in person. Other visits may be in person, on the computer (virtual), or over the telephone.

You will be placed by chance in a group to take either the study drug, GS-5245, or placebo.

The placebo looks like GS-5245 but does not have any active medicine in it. This helps researchers to better understand the effects of GS-5245. You and the study doctor will not know which group you are in. This helps to keep the study fair.

Close
Check your eligibility

Eligibility Checker